Literature DB >> 1837385

Comparative effects of clarithromycin and erythromycin on the normal intestinal microflora.

B Brismar1, C Edlund, C E Nord.   

Abstract

10 healthy volunteers received 250 mg of clarithromycin orally q 12 h for 7 days and 10 other volunteers 1000 mg of erythromycin ethylsuccinate orally q 12 h for 7 days. Stool specimens were collected before, during and after antibiotic administration. In the clarithromycin group, the numbers of streptococci and enterobacteria decreased among aerobic microorganisms while in the erythromycin group streptococci, enterococci and enterobacteria decreased and staphylococci increased during antibiotic administration. The anaerobic intestinal microflora was also affected. The alterations were more pronounced in the volunteers receiving erythromycin than in those having clarithromycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837385     DOI: 10.3109/00365549109105189

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study.

Authors:  Hans F Berg; Jeroen H T Tjhie; Gert-Jan Scheffer; Marcel F Peeters; Peter H J van Keulen; Jan A J W Kluytmans; Ellen E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Authors:  Mamun-Ur Rashid; Staffan Rosenborg; Georgios Panagiotidis; Johan Holm; Karin Söderberg Löfdal; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 3.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

4.  Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

Authors:  Sivaranjani Namasivayam; Mamoudou Maiga; Wuxing Yuan; Vishal Thovarai; Diego L Costa; Lara R Mittereder; Matthew F Wipperman; Michael S Glickman; Amiran Dzutsev; Giorgio Trinchieri; Alan Sher
Journal:  Microbiome       Date:  2017-07-07       Impact factor: 14.650

Review 5.  Factors Explaining Interpersonal Variation in Plasma Enterolactone Concentrations in Humans.

Authors:  Elin Hålldin; Anne Kirstine Eriksen; Carl Brunius; Andreia Bento da Silva; Maria Bronze; Kati Hanhineva; Anna-Marja Aura; Rikard Landberg
Journal:  Mol Nutr Food Res       Date:  2019-03-26       Impact factor: 5.914

Review 6.  Human gut microbiota: repertoire and variations.

Authors:  Jean-Christophe Lagier; Matthieu Million; Perrine Hugon; Fabrice Armougom; Didier Raoult
Journal:  Front Cell Infect Microbiol       Date:  2012-11-02       Impact factor: 5.293

7.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 8.  The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.

Authors:  Amy Langdon; Nathan Crook; Gautam Dantas
Journal:  Genome Med       Date:  2016-04-13       Impact factor: 11.117

Review 9.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10

10.  Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review.

Authors:  Karen T Elvers; Victoria J Wilson; Ashley Hammond; Lorna Duncan; Alyson L Huntley; Alastair D Hay; Esther T van der Werf
Journal:  BMJ Open       Date:  2020-09-21       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.